TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05878860: ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

Sponsor: Atsena Therapeutics Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 97 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$3,347,224

Rescue Site Savings

+$2,215,768

Unlock Full NCT05878860 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05878860 Rescue Dossier →